{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-096935","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.776547+00:00","generated_at":"2026-05-17T04:32:39.664725+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"confidence":"high","headline":"Marker Therapeutics treats first patient in Phase 1 OTS MAR-T cell study; well tolerated","bullets":["First patient dosed at 100x10^6 cells in Phase 1 RAPID study evaluating MT-401 as Off-the-Shelf product.","No treatment-related adverse events observed in first patient; safety consistent with prior MAR-T cell data.","OTS product aims to accelerate time to treatment to as fast as 72 hours using healthy donor material.","Non-dilutive funding from FDA, NIH SBIR, and CPRIT supports OTS program without affecting cash runway.","APOLLO study in lymphoma reported 66% objective response rate and durable complete responses."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-096935","json":"https://secwatch.observer/filing/0001104659-25-096935.json","markdown":"https://secwatch.observer/filing/0001104659-25-096935.md","text":"https://secwatch.observer/filing/0001104659-25-096935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925096935/0001104659-25-096935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925096935/tm2527906d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:32:39.664725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}